CMS makes landmark announcement on replacing 'Meaningful Use' with 'Meaningful Outcomes'

15 January 2016
hhsbig

With a bombshell announcement earlier this week on stage at the JP Morgan Healthcare Conference taking place in San Francisco, the US Centers for Medicare and Medicaid (CMS) is once again taking a major step toward better medical outcomes at a lower cost.

For six years, the $19 billion CMS Meaningful Use program has advanced the adoption of electronic health record technology in the USA. Some say the program has created a gridlock of information technology resources with its complex regulations that confused vendors and CIOs equally.

"The Meaningful Use program as it has existed, will now be effectively over and replaced with something better,” said Andy Slavitt, Acting Administrator for CMS, adding: “Since late last year we have been working side by side with physician organizations across many communities - including with great advocacy from the AMA - and have listened to the needs and concerns of many. We will be putting out the details on this next stage over the next few months, but I will give you [the] themes guiding our implementation.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical